Pomalyst is an anti-cancer drug owned by Bristol Myers Squibb. The active ingredient in Pomalyst is pomalidomide. The drug was first authorized for market use on 08 February, 2013 and is available in capsule;oral dosage forms.
Pomalyst has a total of 12 drug patents, 4 of which have expired. The generic version of Pomalyst could potentially be released after the last patent expires on 21 December, 2031.
Pomalyst is used for the treatment of multiple myeloma. It is specifically used in conjunction with dexamethasone for patients who have had at least two prior therapies including lenalidomide and a proteasome inhibitor, and who have demonstrated disease progression on or within 60 days of completing the last therapy.
Pomalyst holds several patents for its methods of treating multiple myeloma and various formulations of the drug. The latest patent expiration date is 21 December, 2031. Below are the details of the patents: